Rigel Pharmaceuticals, Inc. RIGL

Healthcare — Biotechnology

Cash Flow Champion (3y)

Growth Flags show if company had growth for consecutive years

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16
P/E ratio	2.12	17.52	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
P/S ratio	2.62	1.65	2.17	1.90	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/FCF ratio	10.21	9.45	0.00	0.00	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
P/Operating CF	35.05	20.39	(40.71)	(10.43)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
P/B ratio	1.97	89.93	0.00	0.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Price to Tangible BV	2.10	0.00	0.00	0.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/Sales	2.17	1.51	2.14	1.75	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBITDA	5.04	10.56	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
EV/Operating CF	8.44	8.63	(43.56)	(2.86)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/FCF	8.46	8.67	(12.21)	(2.88)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Quick Ratio	2.08	1.88	1.64	1.51	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡
Current Ratio	2.42	2.13	1.86	1.78	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Debt/EBITDA	(1.05)	(0.97)	0.23	0.32	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Debt/Assets	4.38%	31.96%	44.68%	30.22%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡
Debt/Equity	0.06	15.94	(1.83)	(2.98)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡
Asset Turnover	0.87	1.28	0.93	0.80	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF/Net income	0.21	1.80	0.23	1.26	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex/Depreciation	0.00	(0.20)	(19.42)	0.47	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Depreciation/Fixed assets	0.00	16.51	4.60	1.09	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Coverage	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
ROE	185.94%	(137.92%)	118.75%	(699.05%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
ROA	108.34%	12.44%	(19.95%)	(38.84%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
ROIC	30.28%	0.00%	0.00%	0.00%	‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Cash ROIC	13.30%	23.59%	(7.32%)	(87.61%)	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Return on Tangible Assets	260.43%	24.32%	(54.35%)	(113.63%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Accounts Receivable Turnover	6.30	4.97	3.30	4.31	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
Accounts Payable Turnover	3.73	3.56	0.48	0.13	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
Inventory Turnover	2.24	3.24	0.97	0.22	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	—
Average Days of Receivables	64.20	84.73	95.40	122.39	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
Average Days of Payables	133.77	65.36	366.64	4,697.21	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡
Days of Inventory on Hand	214.04	117.48	283.48	1,902.84	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	—
Research and Development Expense of Revenue	11.31%	13.04%	20.98%	50.13%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Selling, General and Administrative Expense of Revenue	39.38%	63.06%	90.47%	93.52%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Intangible Assets out of Total Assets	0.05	0.17	0.12	0.11	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Share Based Compensation of Revenue	4.32%	6.91%	7.53%	10.30%	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Graham Net Nets	0.15	(0.09)	(0.18)	(0.14)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Graham Number	99.56	2.01	7.45	7.82	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Earnings Yield	47.26%	5.71%	(10.27%)	(25.37%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow Yield	9.79%	10.59%	(8.06%)	(32.09%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Revenue per Share	16.36	10.20	6.72	7.05	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Operating CF per Share	4.21	1.79	(0.33)	(4.33)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capex per Share	0.00	(0.02)	(0.85)	0.03	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow per Share	4.21	1.77	(1.18)	(4.30)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Cash per Share	8.61	4.40	3.27	3.41	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Shareholders Equity per Share	21.76	0.19	(1.65)	(0.80)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Interest Debt per Share	0.00	0.00	0.00	0.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡‡
Book value per Share	21.76	0.19	(1.65)	(0.80)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Free Cash Flow	75.66	31.17	(20.48)	(73.31)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Working Capital	140.93	71.80	46.00	50.69	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Capital Expenditures	—	(0.30)	(14.74)	0.44	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Current Asset Value	118.05	(25.58)	(46.60)	(31.99)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Receivables	46.69	36.08	35.44	27.90	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	—
Average Payables	5.27	5.24	14.83	13.15	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Inventory	8.75	5.76	7.32	7.87	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	—
Average Assets	338.79	140.60	125.75	150.80	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Average Common Equity	197.38	(12.68)	(21.13)	8.38	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
EV/EBIT	5.09	11.22	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡
Capex to Sales	0.00	0.00	0.13	0.00	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Net Profit Margin	124.72%	9.75%	(21.47%)	(48.71%)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Price to Operating Income	6.14	12.22	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now